Paul Lammers, MD, MSc, President and Chief Executive Officer
Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for a private biotech company, Immunomet.
Jonathan Bramson, PhD, Founder and Chairman of Triumvira Scientific Advisory Counsel
Dr. Jonathan Bramson founded Triumvira Immunologics, Inc., along with his post-doctoral Fellow, Dr. Christopher Helsen, in 2015. He is currently a Professor in the Department of Pathology and Molecular Medicine and the Vice Dean (Research) for the Faculty of Health Sciences at McMaster University. He holds a Tier I Canada Research Chair in Translational Cancer Immunology and the John Bienestock Chair in Molecular Medicine. As an immunologist who has been researching novel cancer immune-oncology strategies since 1994, Dr. Bramson’s lab is focused on developing methods to direct cancer patients’ immune systems to attack their tumors. To this end, the lab has been developing novel methods to engineer T cells to attack cancer and designing vaccines based on recombinant viruses to boost immunity against specific tumor antigens. The Bramson lab works closely with clinical partners at the Juravinski Hospital in Hamilton to optimally develop these exciting new immune strategies to address unmet needs of the cancer community in Southern Ontario. Together, Dr. Bramson and his colleagues have established an infrastructure at McMaster, which includes GMP production and GLP correlative assays, for conducting clinical trials of novel immune-oncology therapies that are unparalleled in Canada. Dr. Bramson received his Ph.D. in Experimental Medicine in 1994 from McGill University.
Sabine Chlosta, MD, PhD, Chief Medical Officer
Dr. Sabine Chlosta joined Triumvira in January 2018. Prior to Triumvira, Dr. Chlosta consulted for Aurora BioPharma, a start-up company developing CAR-T cells in solid tumors, and was previously a Senior Medical Director at Merck/MSD where she played a key role in the development of their PD-1 inhibitor Keytruda® in non-Hodgkin lymphoma and also oversaw trials in other indications. Earlier in her career, Dr. Chlosta was a medical director at Glycomimetics where she helped launch the company’s first trial in hematology/oncology. Dr. Chlosta started her career in industry as a Fellow in oncology drug development at Novartis overseeing clinical pharmacology trials with a small molecule and helped the team launch the CAR-T lymphoma program with CTL019, Kymriah®. Dr. Chlosta is board-certified in pediatric hematology-oncology and in pediatrics. She completed post-graduate training in hematology-oncology at the combined program of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College and in pediatrics at State University of New York at Downstate. Prior to entering clinical training in the United States, Dr. Chlosta was a visiting research Fellow in immunology at Harvard. Dr. Chlosta received her PhD degree in Immunology and Infectious Diseases and her MD degree from Charité Medical School / Free University.
Donna Rill, Chief Technology Officer
Ms. Rill joined Triumvira as Chief Technology Officer in June 2018. Prior to Triumvira, Ms. Rill, an accomplished expert in cellular therapy manufacturing, was responsible for the design and qualification of cell & gene therapy laboratories using novel technologies, cGMP vector production facilities, core service laboratories, and translational research laboratories. In addition to her construction, project management and regulatory/QA/QC/(c)GxP knowledge, she brings extensive operational and strategic experience in cell and gene therapy, monoclonal antibody production, and protein production. Ms. Rill will oversee all North American operations for Triumvira.
Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.
Andreas (Andy) Bader, PhD, Chief Scientific Officer
Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years of experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his PhD in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Teresa McRoberts, Chief Financial Officer
Ms. McRoberts brings more than four decades of experience in the financial sector across both the buy-side and sell-side with a focus on healthcare. Prior to joining Triumvira, she was Portfolio Manager, Senior Vice President, and Senior Analyst at Alger Management, a growth-style investment management company, where she grew Alger’s Health Sciences Trust into a top 10% healthcare mutual fund. She was also previously Portfolio Manager at Morgan Stanley, Portfolio Co-Manager at Tribeca Global Management, a hedge fund owned by Citigroup, and an analyst and investment banker with J.P. Morgan. Ms. McRoberts holds a Master of Business Administration from Columbia Business School and a Bachelor of Arts in English from Oberlin College.
Jon Irvin, Senior Vice President, Finance
Mr. Jon Irvin joined Triumvira as the Vice President of Finance in January 2018. Prior to Triumvira, Mr. Irvin was the Chief Financial Officer and Vice President of Finance at Mirna Therapeutics. He also served as the Chief Executive Officer and Vice President of Finance for Voxpath Networks, Inc., a telecommunications and intellectual property company. Previously, Mr. Irvin was in executive financial positions at Reddwerks Corporation, a software company, Esoterix, Inc., a medical laboratory company, Topaz Technologies, a pharmaceutical software company, and BioNumerik Pharmaceuticals, Inc., a pharmaceutical company. Mr. Irvin began his career as an accountant with Price Waterhouse (senior) and Ernst & Young (senior manager). He received a B.S. in Accounting from the University of Illinois, and his Certified Public Accountant designation in California.
Joshua Carle, MBA, VP of Business Development
Joshua Carle, MBA, is a cross-functional executive with over 15 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle joins from Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology. Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.
Cynthia Molina, VP of Regulatory Affairs
Before joining Triumvira, Ms. Molina was most recently VP of Global Regulatory Affairs at Cell Medica, Inc in Houston, TX, for 6 years and accumulated 30 years of experience in multiple facets of product development for pharmaceutical, biotechnology, biologic, and in vitro diagnostic products, with a primary focus on regulatory affairs. In addition to regulatory affairs, her experience includes clinical and preclinical strategic planning, quality assurance, process development and manufacturing for oncology and infectious disease products. Ms. Molina has experience leading preparation of a variety of global regulatory submissions, including INDs, NDAs, BLAs, MAAs, global CTAs, 510Ks, PMAs, orphan and Fast Track submissions, and clinical study reports. She has held management positions at both large and small corporations, including Abbott Laboratories.